# SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Source: https://onco.cc/trials/nct06325748/  
OnCo record `nct06325748` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of SENTI-202 run by Senti Biosciences, active and no longer recruiting.

## Summary

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS is a phase 1 interventional study registered as NCT06325748 by Senti Biosciences, with 21 participants planned, started 2024-04-22. Conditions recorded: AML/MDS, CD33 Expressing Hematological Malignancies and FLT3 Expressing Hematological Malignancies. Interventions recorded: SENTI-202.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06325748
- Phase: 1
- Setting: SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
- Sponsor: Senti Biosciences
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT06325748: https://clinicaltrials.gov/study/NCT06325748

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SENTI-202](https://onco.cc/drugs/senti-202/)
- companies: [Senti Biosciences](https://onco.cc/companies/senti-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06325748.json